Innovation today, healthier tomorrows
Sumitomo Pharma America, Inc. (sunovion.com) scores 73 out of 100 on Brand Analyzer, placing it in the Brand-Ready tier among Healthcare brands, in the 33rd percentile of 14056 Healthcare brands.
Sumitomo Pharma America, Inc. is a pharmaceutical company that develops innovative treatments across oncology, women's health, urology, rare disease, central nervous system (CNS) disorders, and cell & gene therapies. Guided by a mission to improve global health through science and innovation, the company emphasizes patient-first research and scientific rigor. It serves patients, healthcare providers, and researchers seeking advanced therapeutic solutions. The company operates under the Sumitomo Pharma name, reflecting its affiliation with the Japan-based Sumitomo Pharma Co., Ltd.
| Brand Name | Sumitomo Pharma America, Inc. |
|---|---|
| Domain | sunovion.com |
| Industry | Healthcare |
| Parent Company / Owner | Sumitomo Pharma Co., Ltd. |
| Main Competitors | Takeda Pharmaceutical (87/100), Otsuka Pharmaceutical (75/100), Eisai (80/100), Jazz Pharmaceuticals (82/100), Sage Therapeutics (76/100), Supernus Pharmaceuticals (78/100), H. Lundbeck A/S (82/100), AbbVie (84/100), Bayer (80/100), Teva Pharmaceutical Industries (86/100) |
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Sumitomo Pharma America, Inc. advances innovative treatments across oncology, women" (Meta description: 10 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:image, og:type, Twitter cards, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: Vue.
Social footprint: verified profiles on LinkedIn, X (Twitter), YouTube, Facebook, Instagram, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Sumitomo Pharma America, Inc.?", Claude could identify the brand as of October 2026. Sumitomo Pharma America (formerly Sunovion Pharmaceuticals) is a US pharmaceutical company focused on central nervous system and psychiatric disorders, developing and marketing drugs like Latuda for schizophrenia and bipolar depression. It operates as part of Japan's Sumitomo Pha Best known for Developing Latuda (lurasidone), a major atypical antipsychotic drug.
When asked "Best brands similar to Sumitomo Pharma America, Inc.?", Claude would recommend Sumitomo Pharma America, Inc. as of October 2026. It's a well-known player in CNS/psychiatric drug development, so it would come up when discussing major pharma companies in that therapeutic space.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Sumitomo Pharma America, Inc.'s main competitors in Healthcare: Takeda Pharmaceutical (87/100), Otsuka Pharmaceutical (75/100), Eisai (80/100), Jazz Pharmaceuticals (82/100), Sage Therapeutics (76/100).
Sources: Brand Analyzer scan
Sumitomo Pharma America, Inc. has low AI-search visibility, scoring 11/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 4, recommendation 40). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sumitomo Pharma America, Inc. scores 40/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sumitomo Pharma America, Inc. can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sumitomo Pharma America, Inc. scores 11/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Sumitomo Pharma America, Inc. has a weak AI-visibility profile at 11/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (40/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and thin schema.org structured data. In a live check, Claude could already identify Sumitomo Pharma America, Inc. from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Sumitomo Pharma America, Inc.: Sunil Healthcare Ltd (73/100), sunday (73/100), SupportAbility (73/100), Surrey Hospitals Foundation (73/100).
A step up - brands to learn from: Zymo Research (81/100), Zurich Insurance Group (81/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.